Evidence map›Paper›PMID 33061558›Full record

ArticleJournal of pain research2020

An Examination of State and Federal Opioid Analgesic and Continuing Education Policies: 2016-2018.

Kathryn Duensing, Robert Twillman, Stephen Ziegler, M Soledad Cepeda, David Kern, Maribel Salas, Gregory Wedin

Open access · goldAbstract read
In one paragraph

Article in Journal of pain research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Why All Behavioral Health Providers Need Addiction Training.The journal of behavioral health services & research · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Drug-related physician continuing medical education requirements, 2010-2020.Journal of substance use and addiction treatment · 2024
    Article
  7. Observational
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 1 country.

Kathryn DuensingRKT Consulting, LLC, Lenexa, KS, USA.ORCID 0000-0002-3578-0196
Robert TwillmanRKT Consulting, LLC, Lenexa, KS, USA.ORCID 0000-0001-5465-0568
Stephen ZieglerCenter for Effective Regulatory Policy and Safe Access, Denver, CO, USA.
M Soledad CepedaDepartment of Epidemiology, Janssen Research & Development, Titusville, NJ, USA.ORCID 0000-0002-5159-6217
David KernDepartment of Epidemiology, Janssen Research & Development, Titusville, NJ, USA.ORCID 0000-0001-5417-3925
Maribel SalasDepartment of Epidemiology, Clinical Safety and Pharmacovigilance, Daiichi Sankyo, Basking Ridge, NJ, USA.ORCID 0000-0001-5634-1558
Gregory WedinUpsher-Smith Laboratories, LLC, Pharmacovigilance and Risk Management, Maple Grove, MN, USA.
Janssen (United States) · USDaiichi Sankyo (United States) · USIndiana University – Purdue University Fort Wayne · USLEK Consulting (United States) · USSaint Luke's Health System · USUpsher-Smith Laboratories (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionOpioid overdose deaths in the United States have climbed sharply over the past two decades. Simultaneously, increased awareness of inadequately treated chronic pain has resulted in increased opioid analgesic prescribing. The correlation between these two phenomena has led policymakers to posit that they are causally linked, and to implement policy changes supporting safe opioid prescribing. PURPOSE: To evaluate the impact of its Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS) program, the US Food and Drug Administration (FDA) requested the opioid manufacturers responsible for implementing that program provide information regarding opioid policy changes from 2016 to 2018. FDA also requested a survey of state requirements for pain and opioid prescribing continuing education (CE), the number of prescribers affected by those requirements, the extent to which a REMS-compliant CE program would meet each state's requirements, and the number of relevant CE programs available.

resultsResults indicate that 527 federal and state opioid-related policies (statutes, rules/regulations, and guidelines) were approved during the 2016-2018 study period. While the largest number of these policies focused on prescription drug monitoring programs, 170 specifically imposed limits on opioid prescribing and an additional 35 specifically referred to, or incorporated, the Centers for Disease Control and Prevention opioid prescribing guideline. We also found that 46 states and the District of Columbia mandated some amount of pain or opioid prescribing CE for prescribers renewing their licenses. These mandates potentially affected as many as 1.7 million prescribers. In 69% of cases, a REMS-compliant CE program would fully meet the state mandates for various types of prescribers.

conclusionThe severity and complexity of the problems of pain management and opioid overdose have led to large-scale intervention by policymakers. Assessing the impact of these changes is difficult, at best, but will be necessary if interventions are to be refined to increase their effectiveness.

Indexed as

CDCFDA blueprintlawopioidspolicyprescribingREMS

Identifiers

PMID33061558
PMCPMC7534855
OpenAlexW3090091957

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.